Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q04759

UPID:
KPCT_HUMAN

ALTERNATIVE NAMES:
nPKC-theta

ALTERNATIVE UPACC:
Q04759; B4DF52; Q14DH6; Q3MJF1; Q64FY5; Q9H508; Q9H549

BACKGROUND:
The nPKC-theta protein, a serine/threonine-protein kinase, is integral to T-cell receptor (TCR) signaling, facilitating key processes such as T-cell activation and survival. It activates transcription factors like NF-kappa-B and JUN, crucial for IL2 production and immune response. Additionally, nPKC-theta influences platelet function and insulin signaling, underscoring its versatility in cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Protein kinase C theta type unveils potential avenues for therapeutic intervention. Its involvement in critical immune and signaling pathways makes it a target of interest for developing treatments against autoimmune diseases and for improving immunotherapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.